<![CDATA[QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML]]>
From first-generation TKIs such as imatinib (Gleevec), second-generation treatments such as bosutinib (Bosulif), nilotinib (Tasigna), and dasatinib (Sprycel), and even third- and fourth-generation iterations, the arsenal of TKIs at the disposal of …